Abstract
Beta cell replacement and regeneration therapies seem promising approaches to the treatment of insulindependent diabetes. The short supply in beta cells from cadaveric organ donors and the very low replication capacity of human beta cells have spurred efforts to find robust ways of (re-)generating beta cells in vitro and in vivo. In the pancreas, both the capacity of regeneration and the mechanism involved can differ significantly depending on the experimental model, as it has also been found in other organs like the liver. Robust expansion of the beta cell mass in adult rodent pancreas doesnt normally occur after partial (50-70%) pancreatectomy nor after beta cell destruction by streptozotocin or alloxan. However, extensive tissue injury and treatment with certain gastrointestinal hormones, like gastrin and growth factors from the EGF-family can stimulate beta cell regeneration. Whereas a slow rate of beta cell mass expansion can result from beta cell replication, more robust regeneration depends largely on neogenesis from precursor cells. Precursor cells can be derived from stem cells or from pancreatic exocrine cells which are known to retain phenotypic plasticity and can transdifferentiate into, amongst others, endocrine cells. Identifying the conditions involved in the regulation of cellular plasticity and regenerative growth may lead to new pharmacological strategies for the treatment of diabetes.
Keywords: Islets of Langerhans, Neogenesis, Stem cells, Metaplasia, Pancreas, Diabetes
Current Diabetes Reviews
Title: Beta Cell Regeneration
Volume: 2 Issue: 1
Author(s): Luc Bouwens
Affiliation:
Keywords: Islets of Langerhans, Neogenesis, Stem cells, Metaplasia, Pancreas, Diabetes
Abstract: Beta cell replacement and regeneration therapies seem promising approaches to the treatment of insulindependent diabetes. The short supply in beta cells from cadaveric organ donors and the very low replication capacity of human beta cells have spurred efforts to find robust ways of (re-)generating beta cells in vitro and in vivo. In the pancreas, both the capacity of regeneration and the mechanism involved can differ significantly depending on the experimental model, as it has also been found in other organs like the liver. Robust expansion of the beta cell mass in adult rodent pancreas doesnt normally occur after partial (50-70%) pancreatectomy nor after beta cell destruction by streptozotocin or alloxan. However, extensive tissue injury and treatment with certain gastrointestinal hormones, like gastrin and growth factors from the EGF-family can stimulate beta cell regeneration. Whereas a slow rate of beta cell mass expansion can result from beta cell replication, more robust regeneration depends largely on neogenesis from precursor cells. Precursor cells can be derived from stem cells or from pancreatic exocrine cells which are known to retain phenotypic plasticity and can transdifferentiate into, amongst others, endocrine cells. Identifying the conditions involved in the regulation of cellular plasticity and regenerative growth may lead to new pharmacological strategies for the treatment of diabetes.
Export Options
About this article
Cite this article as:
Bouwens Luc, Beta Cell Regeneration, Current Diabetes Reviews 2006; 2 (1) . https://dx.doi.org/10.2174/157339906775473644
DOI https://dx.doi.org/10.2174/157339906775473644 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathophysiological Mechanisms Linking Type 2 Diabetes and Dementia: Review of Evidence from Clinical, Translational and Epidemiological Research
Current Diabetes Reviews Pulmonary Nocardiosis in Pemphigus Vulgaris Patients from Tehran, Iran
Infectious Disorders - Drug Targets Antioxidants and its Properties as Affected by Extrusion Process: A Review
Recent Patents on Food, Nutrition & Agriculture Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Structures Required of Flavonoids for Inhibiting Digestive Enzymes
Anti-Cancer Agents in Medicinal Chemistry Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Current Psychopharmacology Self-Care in Adults with Type 2 Diabetes Mellitus: A Systematic Review
Current Diabetes Reviews Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders A Review on Experimental Methods for Diabetes Induction and Therapeutic Efficacy of Anti-diabetic Drug Loaded Nanoformulation
Current Drug Therapy Case Series Describing an Outbreak of Highly Resistant Vancomycin Staphylococcus aureus (Possible VISA/VRSA) Infections in Orthopedic Related Procedures in Guatemala
Infectious Disorders - Drug Targets Drugs Designed to Improve Endothelial Function: Effects on Erectile Dysfunction
Current Pharmaceutical Design The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir
Current Diabetes Reviews Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies
Current Molecular Medicine Clinical Studies with Paclitaxel - Eluting Stent Systems
Current Pharmaceutical Design Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design BeMORE: A Novel Method for Detection of Adverse Fetal Effects Induced by Drugs
Current Drug Safety Medical Management of Obesity
Current Nutrition & Food Science Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry Epigenetic Modifications Associated with the Pathogenesis of Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets